



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$52.23
Change (%)	▼ 0.73 (1.38%)
Volume	672,645
52 Week Low	\$46.93
Market Cap	\$5,432,766,764
Rolling EPS	1.13
PE Ratio	46.7077
Shares Outstanding	102,582,454

Data as of 04/22/19 4:02 p.m. ET



Recent Headlines & Events

04/18/19

Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019

04/16/19

Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate

03/19/19

Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

SEC Filings

Filing Date	Form
04/12/19	DEFA14A
04/12/19	DEF 14A
03/22/19	CT ORDER
03/21/19	4

Data provided by Nasdaq. Minimum 15 minutes delayed.

Date	Title
05/02/19 5:00 p.m. ET	Q1 2019 Emergent BioSolutions Inc. Earnings Conference Call

Primary IR Contact

Robert G. Burrows
Vice President,
Investor Relations
Emergent BioSolutions Inc.
Phone: (240) 631 3280
Fax: (240) 413-1917
E-mail: burrowsr@ebsi.com